Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients

OncoImmunology

Volumn 6, Issue 2, 2017, Pages

  van Meir, H ^a,b   Nout, R A ^a   Welters, M J P ^a   Loof, N M ^a   de Kam, M L ^b   van Ham, J J ^a   Samuels, S ^c   Kenter, G G ^c   Cohen, A F ^b   Melief, C J M ^d   Burggraaf, J ^b   van Poelgeest, M I E ^a   van der Burg, S H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d ISA Pharmaceuticals   (Netherlands)

Author keywords

Cervical cancer; immunomonitoring; immunosuppression; PD 1; radiotherapy

Indexed keywords

CD11 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CISPLATIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN 7 RECEPTOR; MITOGENIC AGENT; PROGRAMMED DEATH 1 RECEPTOR; T6 ANTIGEN;

ADULT; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; BRACHYTHERAPY; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL FUNCTION; CELL POPULATION; CELL PROLIFERATION; CELL STIMULATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERTHERMIA; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOCYTE DIFFERENTIAL COUNT; MIDDLE AGED; MITOGENESIS; MONOCYTE; MULTIPLE CYCLE TREATMENT; MYELOID-DERIVED SUPPRESSOR CELL; OBSERVATIONAL STUDY; PELVIS LYMPHADENECTOMY; PHENOTYPE; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; UTERINE CERVIX CANCER;

EID: 85011805761     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1267095     Document Type: Article

References (44)

1. Sturdza A, Potter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, Petric P, Segedin B, Jurgenliemk-Schulz IM, Nomden C, et al. Image guided brachytherapy in locally advanced cervical cancer:Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016; 120(3):428-33; PMID:27134181; http://dx.doi.org/S0167-8140(16)31018-0 [pii];10.1016/j.radonc.2016.03.011.
2. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62(5):1462-70; PMID:11888921
3. Jain RK. Normalization of tumor vasculature:An emerging concept in antiangiogenic therapy. Science 2005; 307(5706):58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819
4. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, et al. Angiogenesis and immunity:A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30(1):83-95; PMID:21249423; http://dx.doi.org/10.1007/s10555-011-9281-4
5. Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest 2007; 117(5):1130-6; PMID:17476342; http://dx.doi.org/10.1172/JCI32136
6. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch:Anticancer radioimmunotherapy. Oncoimmunology 2013; 2(9):e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
7. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy:A paradigm shift. J Natl Cancer Inst 2013; 105(4):256-65; PMID:23291374; http://dx.doi.org/10.1093/jnci/djs629
8. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy:Mechanisms of resistance and recurrence. Nat Rev Cancer 2015; 15(7):409-25; PMID:26105538; http://dx.doi.org/10.1038/nrc3958
9. Choi CH, Kang H, Kim WY, Kim TJ, Lee JW, Huh SJ, Lee JH, Kim BG, Bae DS. Prognostic value of baseline lymphocyte count in cervical carcinoma treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2008; 71(1):199-204; PMID:18037578; http://dx.doi.org/10.1016/j.ijrobp.2007.09.024
10. Hoskin PJ, Rojas AM, Peiris SN, Mullassery V, Chong IY. Pre-treatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix. Clin Oncol (R Coll Radiol) 2014; 26(4):179-84; PMID:24439272; http://dx.doi.org/10.1016/j.clon.2013.11.023
11. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338(7):423-8; PMID:9459645; http://dx.doi.org/10.1056/NEJM199802123380703
12. Gorter A, Prins F, van Diepen M, Punt S, van der Burg SH. The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. J Transl Med 2015; 13:295; PMID:26357849; http://dx.doi.org/10.1186/s12967-015-0664-0
13. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8(+)/regulatory T-cell ratio:Which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14(7):2028-35; PMID:18381941; http://dx.doi.org/10.1158/1078-0432.CCR-07-4554
14. Piersma SJ, Jordanova ES, van Poelgeest MIE, Kwappenberg KMC, van der Hulst JM, Drijfhout JW, Melief CJM, Kenter GG, Fleuren GJ, Offringa R, et al. High number of intraepithelial CD8(+) tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007; 67(1):354-61; PMID:17210718; http://dx.doi.org/10.1158/0008-5472.CAN-06-3388
15. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, Kuijjer ML, van Poelgeest MIE, van der Burg SH, et al. Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int J Cancer 2013; 133(12):2884-94; PMID:23740735; http://dx.doi.org/10.1002/ijc.28309
16. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen LP, Boer JM, Melief CJM, van der Burg SH. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009; 15(20):6341-7; PMID:19825956; http://dx.doi.org/10.1158/1078-0432.CCR-09-1652
17. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008; 224:141-65; PMID:18759925; http://dx.doi.org/10.1111/j.1600-065X.2008.00649.x
18. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004; 64(12):4328-37; PMID:15205348; http://dx.doi.org/10.1158/0008-5472.CAN-04-0073
19. Lee YJ, Auh SL, Wang YG, Burnette B, Wang Y, Meng YR, Beckett M, Sharma R, Chin R, Tu T, et al. Therapeutic effects of ablative radiation on local tumor require CD8(+) T cells:changing strategies for cancer treatment. Blood 2009; 114(3):589-95; PMID:19349616; http://dx.doi.org/10.1182/blood-2009-02-206870
20. Tseng CW, Trimble C, Zeng Q, Monie A, Alvarez RD, Huh WK, Hoory T, Wang MC, Hung CF, Wu TC. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2009; 58(5):737-48; PMID:18815785; http://dx.doi.org/10.1007/s00262-008-0596-0
21. Mizunuma M, Yokoyama Y, Futagami M, Aoki M, Takai Y, Mizunuma H. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer. Int J Clin Oncol 2015; 20(5):989-96; PMID:25736530; http://dx.doi.org/10.1007/s10147-015-0807-6
22. Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol 2008; 108(1):106-11; PMID:17945335; http://dx.doi.org/10.1016/j.ygyno.2007.08.089
23. Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren DS, Santegoets SJ, Arens R, de Kam ML, Cohen AF, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med 2016; 8(334):334ra52; PMID:27075626; http://dx.doi.org/10.1126/scitranslmed.aad8307
24. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, Cannon M, Parham GP. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 2000; 48(4):997-1006; PMID:11072156; http://dx.doi.org/10.1016/S0360-3016(00)00769-0
25. Parikh F, Duluc D, Imai N, Clark A, Misiukiewicz K, Bonomi M, Gupta V, Patsias A, Parides M, Demicco EG, et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res 2014; 74(24):7205-16; PMID:25320012; http://dx.doi.org/10.1158/0008-5472.CAN-14-1913
26. Keisari Y, Hochman I, Confino H, Korenstein R, Kelson I. Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments. Cancer Immunol Immunother 2014; 63(1):1-9; PMID:23955682; http://dx.doi.org/10.1007/s00262-013-1462-2
27. Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, Deeg HJ. Hematopoietic stem cell compartment:Acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31(5):1319-39; PMID:7713791; http://dx.doi.org/10.1016/0360-3016(94)00430-S
28. Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol 1961; 5:255-8; PMID:13726497; http://dx.doi.org/10.1088/0031-9155/5/3/302
29. McGuire SM, Bhatia SK, Sun W, Jacobson GM, Menda Y, Ponto LL, Smith BJ, Gross BA, Bayouth JE, Sunderland JJ, et al. Using [18F]Fluorothymidine imaged with positron emission tomography to quantify and reduce hematologic toxicity due to chemoradiation therapy for pelvic cancer patients. Int J Radiat Oncol Biol Phys 2016; 96(1):228-39; PMID:27319286; http://dx.doi.org/10.1016/j.ijrobp.2016.04.009
30. Battaglia A, Buzzonetti A, Martinelli E, Fanelli M, Petrillo M, Ferrandina G, Scambia G, Fattorossi A. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010; 76(5):1546-53; PMID:20338481; http://dx.doi.org/10.1016/j.ijrobp.2009.10.014
31. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24(5):589-602; PMID:24209604; http://dx.doi.org/10.1016/j.ccr.2013.09.014
32. Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D'Souza D, Souhami L, Small W, Jr et al. Hematologic toxicity in RTOG 0418:A phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys 2013; 86(1):83-90; PMID:23582248; http://dx.doi.org/10.1016/j.ijrobp.2013.01.017
33. Albuquerque K, Giangreco D, Morrison C, Siddiqui M, Sinacore J, Potkul R, Roeske J. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys 2011; 79(4):1043-7; PMID:20471182; http://dx.doi.org/10.1016/j.ijrobp.2009.12.025
34. Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, Ferris RL. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013; 109(10):2629-35; PMID:24169351; http://dx.doi.org/10.1038/bjc.2013.645
35. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95(Suppl 1):S43-103; PMID:17161167; http://dx.doi.org/10.1016/S0020-7292(06)60030-1
36. Hellebrekers BWJ, Zwinderman AH, Kenter GG, Peters AAW, Snijders-Keilholz A, Graziosi GCM, Fleuren GJ, Trimbos JB. Surgically-treated early cervical cancer:Prognostic factors and the significance of depth of tumor invasion. Int J Gynecol Cancer 1999; 9(3):212-9; PMID:11240769
37. Pieterse QD, Trimbos JBMZ, Dijkman A, Creutzberg CL, Gaarenstroom KN, Peters AAW, Kenter GG. Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer:A retrospective comparative study. Int J Gynecol Cancer 2006; 16(3):1112-8; PMID:16803494; http://dx.doi.org/10.1111/j.1525-1438.2006.00600.x
38. Sevin BU, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli OR, Averette HE. Prognostic factors of early-stage cervical-cancer treated by radical hysterectomy. Cancer 1995; 76(10):1978-86; PMID:8634988; http://dx.doi.org/10.1002/1097-0142(19951115)76
39. Soisson AP, Soper JT, Clarkepearson DL, Berchuck A, Montana G, Creasman WT. Adjuvant radiotherapy following radical hysterectomy for patients with stage Ib and IIa cervical cancer. Gynecol Oncol 1990; 37(3):390-5; PMID:2351324; http://dx.doi.org/10.1016/0090-8258(90)90374-T
40. Rijkmans EC, Nout RA, Rutten IH, Ketelaars M, Neelis KJ, Laman MS, Coen VL, Gaarenstroom KN, Kroep JR, Creutzberg CL. Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol Oncol 2014; 135(2):231-8; PMID:25172763; http://dx.doi.org/10.1016/j.ygyno.2014.08.027
41. Dimopoulos JC, Petrow P, Tanderup K, Petric P, Berger D, Kirisits C, Pedersen EM, van Limbergen E, Haie-Meder C, Pötter R. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV):Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol 2012; 103(1):113-22; PMID:22296748; http://dx.doi.org/10.1016/j.radonc.2011.12.024
42. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010; 107(26):11895-9; PMID:20547850; http://dx.doi.org/10.1073/pnas.1006500107
43. Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, et al. Monitoring regulatory T cells in clinical samples:Consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother 2015; 64(10):1271-86; PMID:26122357; http://dx.doi.org/10.1007/s00262-015-1729-x
44. G.I.W.G. European Medicines Agency. Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples, EMA/INS/GCP/532137/2010 2012; 1-19.